Matinas BioPharma to Present at the Needham Healthcare Conference NYSE:MTNB

Matinas BioPharma to Present at the Needham Healthcare Conference NYSE:MTNB

News Highlights

BEDMINSTER, N.J., April 08, 2021 (News) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 p.m. ET. The Company will also host investor meetings during the conference.

A live webcast of the Company’s presentation will be available on the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com). A webcast replay will be accessible for 90 days following the live presentation.

About Matinas BioPharma

Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors.

Matinas is developing a portfolio of products based upon its proprietary LNC drug delivery platform, which can solve complex challenges relating to the safe and effective intracellular delivery of both small and larger, more complex molecules.

MAT2203 is an oral, LNC formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, primarily used to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is currently enrolling patients in its second cohort, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the third quarter of 2021.

MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic medicine amikacin, primarily used to treat chronic and acute bacterial infections. The Company has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF) to support development of MAT2501 toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF).

LYPDISO™, the Company’s product candidate intended for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, recently announced data from the ENHANCE-IT study, a head-to-head crossover study evaluating LYPDISO vs. Vascepa in patients with elevated triglycerides. Data demonstrating superior levels of eicosapentaenoic acid (EPA) in the blood with LYPDISO support the potential superior cardioprotective effect of LYPDISO vs. Vascepa. The Company has initiated a process to identity and secure a potential partner to continue development of LYPDISO toward a cardiovascular outcomes indication.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the LNC platform delivery technology, the Company’s strategic focus and the future development of its product candidates, including MAT2203, MAT2501 and LYPDISO, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under “Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.

Investor and Media Contacts

Peter VozzoWestwicke/ICR443-213-0505peter.vozzo@westwicke.com

  • Check the latest Health news updates and information.
  • Please share this news Matinas BioPharma to Present at the Needham Healthcare Conference NYSE:MTNB with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Morgan Stanley sells ETrade custody business in a $ 55 million deal

Morgan Stanley sells ETrade custody business in a $ 55 million deal

In a call with analysts in July 2020 to discuss second-quarter earnings, Gorman’s assessment of ETrade’s RIA custody platform was far from full-throated, ...
Here’s what happened today in European Tech.

Here’s what happened today in European Tech.

– Healthcare app Alan has raised €185 million in a series D round, now bringing the company’s valuation to €1.4 billion. The round saw participation from ...
Finance committee to take on health reform while insurers crack down on Dems plans

Finance committee to take on health reform while insurers crack down on Dems plans

This week the General Assembly’s finance committee is scheduled to take up Lembo’s proposal, Senate Bill 842.  State business groups including the Connecticut ...
The marijuana business evolves with the approval by the Denver City Council of smoking rooms and public use of marijuana on special buses - CBS Denver

The marijuana business evolves with the approval by the Denver City Council of smoking rooms and public use of marijuana on special buses – NewsDenver

The new law is to open the marijuana business for “social equity,” entrepreneurs without big bucks and those negatively impacted by marijuana laws in the past. ...
Apple iPads to support latest PlayStation, Xbox game controllers. Orders for iPad Pro models begin April 30

Apple iPads to support latest PlayStation, Xbox game controllers. Orders for iPad Pro models begin April 30

New iPad Pro models are on the way, too. Starting prices remain the same as the previous generation if iPad Pro devices: the 11-inch model starts at $799, ...
Eden  News Briefs |  News

Eden News Briefs | News

But 63% of business owners in North Carolina are confident in their ability to stay open for at least six months, which is five points below the national ...
Valve Index 2: what do the fans have in mind?

Valve Index 2: what do the fans have in mind?

A sequel device would make sense, even with the device’s high price tag: 16% of all Steam VR users own a Valve Index according to official figures at the ...
Lewis County automotive business strong after pandemic |  News

Lewis County automotive business strong after pandemic | News

A hailstorm that hit Lewis County in early 2020 helped on the body shop side of the business, though. But there were concerns about what repair business would ...
Show next
Compsmag - Latest News from tech, business and health
Logo